“Upregulated LAMA3 Contributes to Cholangiocarcinoma Malignancy and Its Potential as Biomarker and Therapeutic Target”

https://pubmed.ncbi.nlm.nih.gov/38114514

The study suggests that upregulated LAMA3, a laminin subunit, contributes to the malignancy of cholangiocarcinoma by modulating cell proliferation, adhesion, migration, and epithelial-to-mesenchymal transition, highlighting its potential as a diagnostic biomarker and therapeutic target.